A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer
Sara M. Tolaney(Harvard University), Carey K. Anders(Duke University), Peter Kabos(University of Colorado Anschutz Medical Campus), Denise A. Yardley(Sarah Cannon), Solmaz Sahebjam(Johns Hopkins University), PierFranco Conte(University of Padua), Thomas Bachelot(Centre Léon Bérard), Nancy U. Lin(Dana-Farber Cancer Institute), Véronique Dièras(Institut Curie), Yanyun Chen(Eli Lilly (United States)), Zhengyu Yang(Monash University), Émilie Le Rhun(University of Zurich), Sonya C. Chapman(Eli Lilly (United States)), Arlene Chan(Curtin University), Melissa Bear(Eli Lilly (United States)), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell)
Cited by 204
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k